Head to Head Analysis: FIH Mobile (OTCMKTS:FXCNY) and H. Lundbeck A/S (OTCMKTS:HLUYY)

Earnings and Valuation

This table compares FIH Mobile and H. Lundbeck A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FIH Mobile	$6.45 billion	1.41	-$120.68 million	N/A	N/A
H. Lundbeck A/S	$2.59 billion	8.45	$209.69 million	$0.88	25.00

H. Lundbeck A/S has lower revenue, but higher earnings than FIH Mobile.

Profitability

This table compares FIH Mobile and H. Lundbeck A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FIH Mobile	N/A	N/A	N/A
H. Lundbeck A/S	6.74%	13.74%	7.16%

Dividends

FIH Mobile pays an annual dividend of $0.06 per share and has a dividend yield of 0.3%. H. Lundbeck A/S pays an annual dividend of $0.20 per share and has a dividend yield of 0.9%. H. Lundbeck A/S pays out 22.7% of its earnings in the form of a dividend.

Summary

H. Lundbeck A/S beats FIH Mobile on 6 of the 8 factors compared between the two stocks.

About FIH Mobile

FIH Mobile Limited, an investment holding company, provides integrated manufacturing services for the handset industry worldwide. The company designs, manufactures, and trades in handsets, as well as offers repair services. It is also involved in the research and development activity; manufacture and sale of electronic products; and import and export activities. The company was formerly known as Foxconn International Holdings Limited and changed its name to FIH Mobile Limited in May 2013. FIH Mobile Limited was incorporated in 2000 and is headquartered in New Taipei City, Taiwan. FIH Mobile Limited is a subsidiary of Foxconn (Far East) Limited.

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.